Genetic variants associated with immune-mediated liver injury from checkpoint inhibitors
ILICI typically arises within 12 weeks of initiating immunotherapy and is self-limited in most cases. Genetic variants involved in host T-cell regulation and drug disposition were identified, implicating these pathways in the pathogenesis of ILICI. If validated, these findings could lead to improved diagnostic instruments and possible treatments for ILICI.
Authors
- Andrew Stolz (ORCID: https://orcid.org/0000-0002-1443-9351)
- David E. Kleiner (ORCID: https://orcid.org/0000-0003-3442-4453)
- Huiman X. Barnhart (ORCID: https://orcid.org/0000-0003-0988-3439)
- Raj Vuppalanchi (ORCID: https://orcid.org/0000-0003-0637-1577)
- Yi‐Ju Li (ORCID: https://orcid.org/0000-0001-6996-4834)
- Lily Dara (ORCID: https://orcid.org/0000-0002-0121-7186)
- Vincent Chen (ORCID: https://orcid.org/0000-0002-0157-6066)
- Robert J. Fontana (ORCID: https://orcid.org/0000-0001-9161-5892)
- Jiezhun Gu
- J. Odin
Institutions
- University of Southern California (US)
- National Institutes of Health (US)
- Duke University (US)
- University of Michigan (US)
- Clinical Research Institute (US)
- National Cancer Institute (US)
- Indiana University – Purdue University Indianapolis (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Hepatology Communications
- Published
- 2024-08-26
- DOI
- https://doi.org/10.1097/hc9.0000000000000518
- Citations
- 11
- Primary Topic
- Drug-Induced Hepatotoxicity and Protection
- Type
- article
- Field-Weighted Citation Impact
- 5.14